Shop by goal
Popular compounds
Research resources
Recently viewed
Premium research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical with a Certificate of Analysis on every lot. Shipped lab-direct, discreet and cold-chain, worldwide. For laboratory research use only.
Shop
Learn
Company
Support
Ways to Pay
Shop by Compound
Shop by Goal
Ships worldwide
Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.
All rights reserved. Copyright of New-U held with Hilxera Distribution Services LLC 2026.
Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.
© 2026 New-U Research Compounds · new-u.io · @new.u.io
Cartalax
Pick your pack · how long it lasts
At 1.40 mg/wk — select pack size
Lab-direct quality — full packs or single-vial samples
Every batch ships straight from the lab that synthesises it — sealed, tamper-evident, and HPLC-verified to >99% purity with a batch-linked Certificate of Analysis. Buying direct means you pay the lab-direct rate on every vial, with nothing stacked on top.
Order a full sealed 10-vial research pack for a complete study supply, or add a single-vial sample alongside your pack to trial a new compound first. Same lab, same batch, same verified purity — scaled to whatever your research needs.
What It's Researched For
In plain terms, Cartalax is studied as a "bioregulator" peptide aimed at connective tissue and cartilage. Here is what that looks like across the research.
Cartilage & connective tissue
Research explores how this tiny peptide influences the cells that build and maintain cartilage and connective tissue as they age.
Gene-expression research
Studied as a tissue-specific switch that can nudge which genes connective-tissue cells turn on or off — the core idea behind the Khavinson "bioregulator" peptides.
Tissue-ageing models
Used as a reference compound in cell-culture work on how connective tissue loses function with age.
Bioregulator family tool
Sits alongside Epitalon and Vesugen as a well-defined member of the short-peptide bioregulator family for comparative research.
Overview
Cartalax (Ala-Glu-Asp, "AED") is a three-amino-acid peptide bioregulator from the Khavinson cytogen family, studied for tissue-specific gene modulation in cartilage and connective-tissue cell models.
Cartalax is one of the shortest peptides you will find in research use — just three amino acids (Ala-Glu-Asp). It comes from the Russian "bioregulator peptide" programme led by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, the same group behind Epitalon (the pineal AEDG tetrapeptide) and Vesugen (the vascular KED tripeptide).
The programme's guiding idea is that the body uses very short peptides as tissue-specific regulators: small enough to enter the nucleus, they are proposed to bind particular sequences in genomic DNA and influence which genes a given tissue expresses. Each cytogen peptide is matched to a tissue — and Cartalax is the connective-tissue / cartilage member of that set. In cultured chondrocyte and fibroblast models it has been studied for its effect on cell proliferation and on the expression of matrix-remodelling and inflammatory-signalling markers tied to connective-tissue ageing.
Cartalax is supplied here as a research-grade lyophilised powder for in-vitro and preclinical work only. It is not an approved medicine in any jurisdiction, and nothing on this page is medical advice.
Mechanism of Action
Cartalax is studied as a tissue-specific transcriptional modulator: the Khavinson model proposes that short peptides enter the nucleus, bind defined promoter sequences, and shift gene expression toward a more youthful pattern in their target tissue — for Cartalax, connective tissue and cartilage.
Cartalax belongs to the "cytogen" class of short synthetic peptides characterised by the Khavinson group, whose foundational hypothesis is that 2–4 residue peptides act as endogenous gene regulators binding specific DNA sequences. Published work on this peptide family describes tissue-matched effects on gene expression and cell proliferation in vitro; the cartilage/connective-tissue assignment of Cartalax (AED) follows that same matched-tissue logic. Formal human pharmacokinetic and controlled clinical efficacy data for Cartalax specifically have not been published, so the mechanism is best framed as a research hypothesis supported by cell-culture and animal studies rather than established human pharmacology.
Common Questions People Are Asking
What is Cartalax used for in research?
Cartalax (Ala-Glu-Asp / AED) is studied as a tissue-specific short-peptide bioregulator focused on cartilage and connective tissue. Research has examined its influence on chondrocyte and fibroblast proliferation and on gene-expression markers tied to connective-tissue ageing, mostly in cell-culture and animal models. It is supplied here for laboratory research only and is not for human use.
What does "AED" mean and how is Cartalax related to Epitalon?
AED is the one-letter code for the sequence Alanine-Glutamate-Aspartate — the three amino acids that make up Cartalax. It belongs to the same Khavinson "cytogen" peptide family as Epitalon (AEDG, four residues) and Vesugen (KED). They share a common design idea — very short peptides acting as tissue-specific gene regulators — but each is matched to a different tissue, with Cartalax assigned to cartilage / connective tissue.
How is Cartalax proposed to work?
The Khavinson bioregulator model proposes that short peptides like Cartalax are small enough to enter the cell nucleus, bind specific promoter sequences in DNA, and modulate the transcription of genes in their target tissue. For Cartalax that target is connective tissue. This is a research hypothesis supported by in-vitro and animal data rather than established human pharmacology.
Is there human clinical data for Cartalax?
No controlled human pharmacokinetic or efficacy data for Cartalax specifically has been published. Most of the evidence comes from cell-culture and animal studies on the short-peptide bioregulator family. It remains a research compound, not a validated therapy, and is sold here strictly for laboratory use.
How should Cartalax be stored?
Keep the lyophilised powder frozen at −20 °C. After reconstitution with bacteriostatic water or sterile saline, refrigerate at 1–6 °C and protect from light. As a small, simple tripeptide it tolerates standard peptide-handling conditions well within the normal usage window.
Where can I buy Cartalax?
Right here — Cartalax is supplied directly by New-U Research Compounds on this page. Every batch is independently third-party tested to >99% HPLC purity with a batch-linked Certificate of Analysis, supplied as lyophilised research-grade material, and shipped direct from source worldwide in discreet, tracked packaging. Strictly for laboratory research use only — not for human use.
How much does Cartalax cost?
Cartalax pricing is shown live on this page, per pack size — 10-vial research packs as standard, with single-vial sample options on selected compounds. Larger vial strengths lower the per-mg cost, every order includes the batch Certificate of Analysis, and shipping is free on orders over $300.
Is Cartalax third-party tested?
Yes. Every Cartalax batch is verified by independent laboratories (Janoshik Analytics and Freedom Diagnostics) for identity and purity, with a batch-linked Certificate of Analysis confirming >99% purity by HPLC. Every order ships with its COA, and current batch certificates are published on our COA page.
How do I buy Cartalax?
Add the Cartalax pack size you need to your cart and check out: enter your shipping details, then choose your payment method — cryptocurrency or card — on the next step. Every order ships with its batch Certificate of Analysis (COA). Cartalax is supplied strictly for laboratory research use only, not for human or veterinary use.
What payment methods can I use to buy Cartalax?
At checkout you can pay by cryptocurrency (BTC, ETH, SOL, LTC, USDC, USDT and more) or by card, each handled by a dedicated secure payment provider. You choose your method after confirming your order.
How fast is shipping, and do you ship worldwide?
Yes — we ship worldwide in discreet, unmarked, temperature-stable, tracked packaging. Delivery typically takes 6–14 business days, and shipping is free on orders over $300.
Is it legal to buy Cartalax?
In the United States, Cartalax is sold strictly for laboratory and research purposes only. It is not approved by the FDA for human consumption and is not sold for that purpose. Regulatory status varies by jurisdiction — buyers are responsible for compliance in their own region.
Pharmacokinetics
Evidence Tier
Overall: Tier 3: Anecdotal / self-report
Cartalax has minimal published evidence: no controlled human pharmacokinetic or efficacy data exist for the compound specifically, and the supporting data are generic cell-culture and animal studies of the Khavinson "cytogen" short-peptide bioregulator family rather than Cartalax itself. Its tissue-specific gene-regulation mechanism is a research hypothesis, not established pharmacology. It has no Western regulatory approval and is supplied as unapproved laboratory material.
Source References & Further Reading
Last reviewed: 26 June 2026 · New-U Research Compounds
Key Characteristics
Specifications
About Cartalax (AED): Connective-Tissue Peptide Bioregulator Research Guide
Cartalax sits inside one of the more distinctive research lineages in peptide science — the Russian "bioregulator peptide" programme run by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Over several decades that group characterised a series of very short peptides (two to four amino acids) which they proposed act as endogenous, tissue-specific gene regulators. Each peptide in the set is matched to a tissue; Cartalax, the Ala-Glu-Asp (AED) tripeptide, is the connective-tissue and cartilage member of the family.
The mechanism that defines the whole family is direct gene regulation by short peptides. The hypothesis is that these peptides are small enough to enter the nucleus, bind specific promoter sequences in DNA, and shift transcription toward a more youthful expression pattern in their target tissue. For Cartalax that means research interest in chondrocyte and fibroblast behaviour — proliferation, matrix remodelling, and the inflammatory-signalling markers associated with connective-tissue ageing — studied largely in cell-culture and animal models rather than controlled human trials.
New-U Research Compounds supplies Cartalax as a research-grade lyophilised powder at 99.31% HPLC purity, verified by an independent third-party lab (Janoshik, task #196370, June 2026). All material is strictly for in-vitro and preclinical research use. Cartalax is not approved for human therapeutic use in any major jurisdiction, and nothing on this page constitutes medical advice or a dosing recommendation.
Customer Reviews
No customer reviews yet — be the first to share your experience.
More in Metabolic / Longevity
Cartalax vs related Metabolic / Longevity compounds
Descriptive catalog comparison for research sourcing decisions — not dosing guidance. All compounds are for laboratory research use only.